Illumina (NASDAQ:ILMN) Hits New 1-Year Low - Here's Why

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) hit a new 52-week low on Tuesday . The stock traded as low as $99.33 and last traded at $100.01, with a volume of 1715757 shares changing hands. The stock had previously closed at $100.24.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ILMN shares. Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Royal Bank of Canada reduced their price objective on Illumina from $250.00 to $247.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Stephens increased their price objective on Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a report on Tuesday, November 12th. Morgan Stanley reduced their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a report on Tuesday, February 11th. Finally, Citigroup lowered Illumina from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $159.45.

Illumina Stock Down 3.1 %

The stock has a 50 day moving average price of $128.97 and a 200-day moving average price of $134.16. The stock has a market capitalization of $14.92 billion, a P/E ratio of -12.27, a PEG ratio of 1.70 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Institutional Trading of Illumina

Large investors have recently bought and sold shares of the company. Mackenzie Financial Corp lifted its holdings in shares of Illumina by 9.5% during the fourth quarter. Mackenzie Financial Corp now owns 21,194 shares of the life sciences company's stock valued at $2,832,000 after purchasing an additional 1,839 shares during the last quarter. North Star Asset Management Inc. lifted its holdings in shares of Illumina by 6.4% during the fourth quarter. North Star Asset Management Inc. now owns 85,604 shares of the life sciences company's stock valued at $11,439,000 after purchasing an additional 5,160 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Illumina during the fourth quarter valued at approximately $445,000. Sunbelt Securities Inc. lifted its holdings in shares of Illumina by 144.4% during the fourth quarter. Sunbelt Securities Inc. now owns 716 shares of the life sciences company's stock valued at $96,000 after purchasing an additional 423 shares during the last quarter. Finally, GTS Securities LLC lifted its holdings in shares of Illumina by 7,215.2% during the fourth quarter. GTS Securities LLC now owns 2,348 shares of the life sciences company's stock valued at $314,000 after purchasing an additional 2,381 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.